<DOC>
	<DOCNO>NCT01798004</DOCNO>
	<brief_summary>This pilot clinical trial study busulfan , melphalan , stem cell transplant chemotherapy treat patient newly diagnose neuroblastoma likely come back spread . Giving chemotherapy entire body stem cell transplant stop growth tumor cell stop divide kill . After treatment , stem cell collect patient 's blood store . More chemotherapy radiation therapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy .</brief_summary>
	<brief_title>Busulfan , Melphalan , Stem Cell Transplant After Chemotherapy Treating Patients With Newly Diagnosed High-Risk Neuroblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine acute toxicity autologous stem cell transplant busulfan-melphalan ( BuMel ) base regimen tolerable give consolidation therapy high-risk neuroblastoma . EXPLORATORY OBJECTIVES : I . To determine incidence non-hematologic organ toxicity ( grade 3 high ) cause mortality patient undergo autologous stem cell transplant BuMel base regimen follow local radiotherapy treatment high-risk neuroblastoma . II . To describe response rate , event-free survival ( EFS ) , overall survival ( OS ) patient undergo induction therapy follow consolidation myeloablative BuMel preparative regimen local radiotherapy treatment high-risk neuroblastoma . III . To correlate busulfan pharmacokinetics non-hematologic toxicity follow BuMel base autologous transplant regimen event-free survival overall survival . IV . To determine feasibility perform Curie score `` real time , '' assess central scan committee review 123 I-meta-iodobenzylguanidine ( MIBG ) scan obtain cycle 4 induction therapy . V. To examine concordance central reviewer institutional reviewer perform Curie score diagnosis cycle 4 induction therapy . VI . To determine feasibility detect aberration anaplastic lymphoma kinase ( ALK ) gene tumor obtain time diagnosis patient high-risk neuroblastoma . VII . To determine feasibility perform molecular profiling neuroblastoma tumor obtain time diagnosis patient high-risk neuroblastoma . VIII . To correlate melphalan pharmacokinetics non-hematologic toxicity follow BuMel base autologous transplant regimen event-free survival overall survival . OUTLINE : INDUCTION THERAPY : COURSES 1-2 : Patients receive cyclophosphamide intravenously ( IV ) 15-30 minute , topotecan hydrochloride IV 30 minute day 1-5 filgrastim subcutaneously ( SC ) IV daily ( QD ) begin day 6 pegfilgrastim SQ day 6 . Treatment repeat every 3 week 2 course . COURSES 3 AND 5 : Patients receive cisplatin IV 1 hour day 1-4 etoposide IV 1-2 hour day 1-3 filgrastim subcutaneously ( SC ) IV daily ( QD ) begin day 6 pegfilgrastim SQ day 6 . Treatment repeat every 3 week 2 course . COURSE 4 : Patients receive cyclophosphamide IV 1-6 hour day 1-2 , vincristine sulfate IV 1 minute day 1-3 , doxorubicin hydrochloride IV 24 hour day 1-3 mesna IV 15-30 minute day 1-2 filgrastim subcutaneously ( SC ) IV daily ( QD ) begin day 6 pegfilgrastim SQ day 6 . Treatment repeat every 3 week 1 course . Treatment continue absence disease progression unacceptable toxicity . CONSOLIDATION THERAPY : Beginning 4-8 week follow 5th course induction therapy , patient receive busulfan IV 3 hour day -6 -3 melphalan IV day -1 . Patients undergo autologous stem cell transplant ( ASCT ) day 0 filgrastim SC IV begin day 0 recovery . Some patient also undergo external beam radiation therapy ( EBRT ) induction consolidation . After completion study treatment , patient follow every 3 month 1 year , every 6 month 4 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Patients must diagnosis neuroblastoma ( International Classification Diseases Oncology [ ICDO ] morphology 9500/3 ) ganglioneuroblastoma ( nodular intermixed ) verify histology demonstration clump tumor cell bone marrow elevate urinary catecholamine metabolite ; patient follow disease stage diagnosis eligible , meet specified criterion Patients newly diagnose neuroblastoma International Neuroblastoma Staging System ( INSS ) stage 4 eligible following : Vmyc avian myelocytomatosis viral oncogene neuroblastoma derive homolog ( MYCN ) amplification ( &gt; 4fold increase MYCN signal compare reference signal ) , regardless age additional biologic feature Age &gt; 18 month ( &gt; 547 day ) regardless biologic feature Age 1218 month ( 365547 day ) follow 3 unfavorable biologic feature ( MYCN amplification , unfavorable pathology and/or deoxyribonucleic acid [ DNA ] index = 1 ) biologic feature indeterminate/unsatisfactory/unknown Patients newly diagnose neuroblastoma INSS stage 3 eligible following : MYCN amplification ( &gt; 4fold increase MYCN signal compare reference signal ) , regardless age additional biologic feature Age &gt; 18 month ( &gt; 547 day ) unfavorable pathology , regardless MYCN status Patients newly diagnose neuroblastoma INSS stage 2A/2B MYCN amplification ( &gt; 4fold increase MYCN signal compare reference signal ) , regardless age additional biologic feature Patients newly diagnose neuroblastoma INSS stage 4S MYCN amplification ( &gt; 4fold increase MYCN expression signal compare reference signal ) , regardless additional biologic feature Patients &gt; = 365 day initially diagnose neuroblastoma INSS stage 1 , 2 , 4S progress stage 4 without interval chemotherapy ; patient must enrol ANBL00B1 ; study enrollment ANBL12P1 must occur within 4 week progression stage 4 INSS stage 1 , 2 , 4S Patients must prior systemic therapy except localized emergency radiation sit lifethreatening functionthreatening disease and/or 1 cycle chemotherapy per low intermediate risk neuroblastoma regimen ( per P9641 , A3961 , ANBL0531 , similar ) prior determination MYCN amplification status histology Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 serum creatinine base age/gender follow : Age 1 month &lt; 6 month : 0.4 mg/dL Age 6 month &lt; 1 year : 0.5 mg/dL Age 1 &lt; 2 year : 0.6 mg/dL Age 2 &lt; 6 year : 0.8 mg/dL Age 6 &lt; 10 year : 1 mg/dL Age 10 &lt; 13 year : 1.2 mg/dL Age 13 &lt; 16 year : 1.5 mg/dL ( male ) , 1.4 mg/dL ( female ) Age &gt; = 16 year : 1.7 mg/dL ( male ) , 1.4 mg/dL ( female ) Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age , Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; 10 x ULN age Shortening fraction &gt; = 27 % echocardiogram , Ejection fraction &gt; = 50 % radionuclide evaluation No know contraindication peripheral blood stem cell ( PBSC ) collection ; example contraindication might weight size less determined feasible collect institution , physical condition would limit ability child undergo apheresis catheter placement ( necessary ) and/or apheresis procedure All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Patients 1218 month age INSS stage 4 3 favorable biologic feature ( ie , nonamplified MYCN , favorable pathology , DNA index &gt; 1 ) eligible Female patient pregnant ineligible Lactating female eligible unless agree breastfeed infant Female patient childbearing potential eligible unless negative pregnancy test result obtain Sexually active patient reproductive potential eligible unless agree use effective contraceptive method duration study participation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>